Investigating the Plasma Lipoprotein Response to a Single Subcutaneous Dose of Analogue Glucagon-like Peptide-2 in Humans

Trial Profile

Investigating the Plasma Lipoprotein Response to a Single Subcutaneous Dose of Analogue Glucagon-like Peptide-2 in Humans

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 22 Feb 2018

At a glance

  • Drugs Teduglutide (Primary)
  • Indications Hyperlipidaemia
  • Focus Pharmacodynamics
  • Acronyms GLP-2 Plasma
  • Most Recent Events

    • 08 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top